Prodromal Schizophrenia

3

Review clinical trials related to Prodromal Schizophrenia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Effects of NAC on Symptoms of CHR Patients

Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals has been shown to help prevent psychosis. Current medications used for CHR symptoms, however, are associated with substantial side effect burden. Therefore, practice guidelines do not recommend current medications as routine treatment for the CHR state, and there is a need to identify new treatments for this condition. Research suggests that abnormal brain oxidative stress may contribute to schizophrenia, offering a potential novel treatment target in the CHR state. Oxidative stress is an excess of free radicals, which are generated from normal metabolism and environmental exposures, and can damage cells. Antioxidants in the body normally neutralize free radicals. Antioxidant deficiency could result in excess oxidative stress that damages brain cells, leading to schizophrenia. Recent studies suggest that N-acetylcysteine (NAC), a precursor of the most abundant brain antioxidant, glutathione, may be a safe, well-tolerated treatment for schizophrenia. In light of this, NAC may also reduce symptoms and brain abnormalities in CHR patients.

Participants needed: 90
Trial details
Age: 16-35Biological sex: AllType: InterventionalSponsor: Centre for Addiction and Mental HealthUpdated: Mar 27, 2026Locations: 1
Eligibility criteria

meeting Criteria of Psychosis-Risk Syndromes (COPS) criteria on the Structured I... [+2]

meeting criteria for any other DSM-5 diagnosis at the time of the study (except... [+10]

Status: Recruiting

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.

Participants needed: 48
Trial details
Phase: Phase 2Age: 13-45Biological sex: AllType: InterventionalSponsor: China Medical University HospitalUpdated: Mar 24, 2026Locations: 1
Eligibility criteria

Individuals meeting Criteria of Prodromal Syndrome (at least one of the followin... [+3]

DSM-5 diagnosis of intellectual disability, substance (including alcohol) use di... [+4]

Status: Recruiting

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

Participants needed: 54
Trial details
Age: 14-20Biological sex: AllType: InterventionalSponsor: Northwell HealthUpdated: Nov 24, 2025Locations: 1
Eligibility criteria

Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis... [+1]

Any DSM 5 Schizophrenia-Spectrum diagnosis [+6]